Tactile Systems Q2 revenue up 9%, slightly beats estimates

Tactile Systems Technology

10/08/2026 21:21

Overview
US medical device maker's Q2 revenue rose 9%, slightly beating analyst expectations
Adjusted EBITDA for Q2 beat analyst expectations
Company repurchased $5.3 mln of stock during the quarter

Outlook
Company now sees 2026 revenue at $360 mln to $366 mln, down from $360 mln to $368 mln
Company maintains 2026 adjusted EBITDA guidance at $49 mln to $51 mln
Revised outlook reflects confidence in lymphedema line, but cautious view on airway clearance sales

Result Drivers
LYMPHEDEMA PRODUCT GROWTH - Revenue growth was driven by a 12% increase in sales and rentals of the lymphedema product line
AIRWAY CLEARANCE DECLINE - Airway clearance product sales fell 7% due to temporary inventory management dynamics linked to the launch of the next-generation AffloVest system
GROSS MARGIN IMPROVEMENT - Gross margin rose to 76% from 75% due to continued operating execution and product cost discipline

Company press release: ID:nGNX9YMcHC

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
Slight Beat*
$85.70 mln
$85.52 mln (5 Analysts)
Q2 EPS
 
$0.34
 
Q2 Net Income
 
$7.80 mln
 
Q2 Adjusted EBITDA
Beat
$11.41 mln
$8.007 mln (4 Analysts)
Q2 Operating Income
 
$6.82 mln
 
*Applies to a deviation of less than 1%; not applicable for per-share numbers.

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"
Wall Street's median 12-month price target for Tactile Systems Technology, Inc. is $40.00, about 35.6% above its August 7 closing price of $29.50
The stock recently traded at 23 times the next 12-month earnings vs. a P/E of 19 three months ago

Reuters Recommended Reads
Aug 10 - Accendra Health Q2 profit, revenue miss estimates on large payor exit
Aug 10 - Heron Therapeutics Q2 revenue rises on acute care growth, withdraws 2026 outlook
Aug 10 - Quanterix Q2 revenue rises 34% but cuts 2026 outlook

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)